Molekulare Wechselwirkungen zwischen Komplement-, Gerinnungs- und Fibrinolysesystem

K. T. Preissner; G. Müller-Berghaus

doi:10.1055/s-0038-1655140

Hämostaseologie, Table of Contents

Hamostaseologie 1986; 06(02): 67-81
DOI: 10.1055/s-0038-1655140

Originalarbeiten

Schattauer GmbH

Molekulare Wechselwirkungen zwischen Komplement-, Gerinnungs- und Fibrinolysesystem

Authors

K. T. Preissner

¹Klinische Forschungsgruppe für Blutgerinnung und Thrombose der Max-Planck-Gesellschaft am Klinikum der Universität Gießen
G. Müller-Berghaus

¹Klinische Forschungsgruppe für Blutgerinnung und Thrombose der Max-Planck-Gesellschaft am Klinikum der Universität Gießen

Abstract

Full Text

References

LITERATUR
1 Almeda S, Rosenberg R D, Bing D H. The binding properties of human complement component Clq. Interaction with mucopolysaccharides. J Biol Chem 1983; 258: 785.
2 Alper C A, Rosen F S. Inherited deficiencies of complement proteins in man. Springer Semin Immunopathol 1984; 07: 251.
3 Asch A S, Konoshita T, Jaffe E A, Nussenzweig V. Human umbilical vein endothelial cells synthesize decay accelerating factor. Blood 1985; 66: 354a.
4 Baker P J, Lint T F, McLeod B C, Behrends C L, Gewürz H. Studies on the inhibition of C56-induced lysis (reactive lysis). VI. Modulation of C56-induced lysis by polyanions and polycations. J Immunol 1975; 114: 554.
5 Bertina R M, van Wijngaarden A, Reinalda-Poot J, Poort S R, Bom V JJ. Immunologic assays for total protein S (PS) and C4b-binding protein (C4bBP) in plasma. Thromb Haemostas 1985; 54: 57.
6 Bhakdi S, Ey P, Bhakdi-Lehnen B. Isolation of the terminal complement complex from target sheep erythrocyte membranes. Biochim Biophys Acta 1976; 419: 448.
7 Bhakdi S, Tranum-Jensen J. Molecular nature of the complement lesion. Proc Natl Acad Sci USA 1978; 75: 5655.
8 Bhakdi S, Tranum-Jensen J. Membrane damage by complement. Biochim Biophys Acta 1983; 737: 343.
9 Bhakdi S, Tranum-Jensen J. On the cause and nature of C9-related heterogeneity of terminal complement complexes generated on target erythrocytes through the action of whole serum. J Immunol 1984; 133: 1453.
10 Bloom H L, Thomas D P. (Eds). Haemostasis and Thrombosis. Churchill Livingstone; Edingburgh: 1981
11 Bohn E, Müller-Berghaus G. The effect of leukocyte and platelet transfusion on the activation of intravascular coagulation by endotoxin in granulocytopenic and thrombocytopenic rabbits. Am J Pathol 1976; 84: 239.
12 Booyse F M, Osikowicz G, Feder S, Scheinbuks J. Isolation and characterization of a urokinase-type plasminogen activator (M_r = 54,000) from cultured human endothelial cells indistinguishable from urinary urokinase. J Biol Chem 1984; 259: 7198.
13 Borsos T, Rapp H R, Mayer M M. Studies on the second component of complement. II. The nature of the decay of EAC 1,4,2. J Immunol 1961; 87: 326.
14 Boyer J T, Gall E P, Norman M E, Nilsson U R, Zimmerman T S. Hereditary deficiency of the seventh component of complement. J Clin Invest 1975; 56: 905.
15 Branson H E, Wyatt D O, Schmer G. Complement consumption in acute disseminated intravascular coagulation without antecedent immunopathology. Am J Clin Pathol 1976; 66: 967.
16 Cazenave J-P, Assimeh S N, Painter R H, Packham M A, Mustard J F. Clq inhibition of the interaction of collagen with human platelets. J Immunol 1976; 116: 162.
17 Cochrane C G, Griffin J H. The biochemistry and pathophysiology of the contact system of plasma. Adv Immunol 1982; 33: 241.
18 Colman R W. Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun 1969; 351: 273.
19 Colman R W, Hirsh J, Marder V J, Salzman E W. (Eds). Hemostasis and Thrombosis. Lippincott; Philadelphia: 1982
20 Cooper N R. Enzymatic activity of the second component of complement. Biochemistry 1975; 14: 4245.
21 Cooper N R. The classical complement pathway: activation and regulation of the first complement component. Adv Immunol 1985; 37: 151.
22 Cooper N R, Miles L A, Griffin J H. Effects of plasma kallikrein and plasmin on the first complement component. J Immunol 1980; 124: 1517.
23 Dahlbäck B. Interaction between vitamin K-dependent protein S and the complement protein, C4b-binding protein. Sem Thromb Hemostas 1984; 10: 139.
24 Dahlbäck B, Hildebrand B. Degradation of human complement component C4b in the presence of the C4b-binding protein protein S complex. Biochem J 1983; 209: 857.
25 Dahlbäck B, Podack E R. Characterization of human S-protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group. Biochemistry 1985; 24: 2368.
26 Dahlbäck B, Stenflo J. High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein. Proc Natl Acad Sci USA 1981; 78: 2512.
27 Davie E W, Fujikawa K. Basic mechanisms in blood coagulation. Ann Rev Biochem 1975; 44: 799.
28 Davie E W, Hanahan D J. Blood coagulation proteins. In: Putnam F W. (Ed): The Plasma Proteins. Vol. 3 Academic Press; New York: 1977: 421.
29 Davie E W, Ratnoff O D. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310.
30 Delvos U, Gajdusek C, Sage H, Harker L A, Schwartz S M. Interactions of vascular wall cells with collagen gels. Lab Invest 1982; 46: 61.
31 Delvos U, Müller-Berghaus G. Die Bedeutung des Endothels der Gefäßwand für die Aufrechterhaltung der Hämostase. Klin Wschr 1985; 63: 1237.
32 Dierich M P, Scheiner O, Mussel H-H, Hamman K, Schope R E, Schulz T. Characterization of complement receptors. Mol Immunol 1982; 19: 1255.
33 DiScipio R G. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 1982; 45: 587.
34 Donaldson V H. Mechanism of activation of Cl esterase in hereditary angioneurotic edema in vitro. The role of Hageman factor, a clot-promoting agent. J Exp Med 1967; 127: 411.
35 Donaldson V H, Evans R R. A biochemical abnormality in hereditary angioneurotic edema. Absence of serum inhibitor of Cl-esterase. Am J Med 1963; 35: 37.
36 Dourmashkin R R. The structural events associated with the attachment of complement components to cell membranes in reactive lysis. Immunology 1978; 35: 205.
37 Esmon N L, Caroll R C, Esmon C T. Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol Chem 1983; 258: 12238.
38 Esmon C T, Esmon N L. Protein C activation. Sem Thromb Haemostas 1984; 10: 122.
39 Esmon C T, Esmon N L, Harris K W. Complex formation between thrombin and thrombomodulin inhibits both thrombincatalyzed fibrin formation and factor V activation. J Biol Chem 1982; 257: 7944.
40 Esmon C T, Owen W G. Identification of an endothelial cell cofactor for thrombincatalyzed activation of Protein C. Proc Natl Acad Sci USA 1981; 78: 2249.
41 Esmon N L, Owen W G, Esmon C T. Isolation of a membrane-bound cofactor for thrombin catalyzed activation of Protein C. J Biol Chem 1982; 257: 859.
42 Fair D S, Sundsmo J S, Schwartz B S, Edgington T S, Müller-Eberhard H J. Prothrombin activation by Factor B(Bb) of the alternative pathway of complement. Thromb Haemostas 1981; 46: 301A.
43 Fearon D T. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Nat Acad Sci USA 1979; 76: 5867.
44 Fearon D T, Austen K F. The alternative pathway of complement — A system for host resistance to microbial infection. N Engl J Med 1980; 303: 259.
45 Fiedel B A, Gewürz H. Complement (Clq), polyanions and platelet activation. Thromb Res 1980; 19: 729.
46 Fishman A P. (Ed). Endothelium. Ann NY Acad Sci. 1982: 401.
47 Forbes C D, Pensky J, Ratnoff O D. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum Cl inactivator. J Lab Clin Med 1970; 76: 809.
48 Fujikawa K, Heimark R L, Kurachi K, Davie E W. Activation of bovine Factor XII (Hageman Factor) by plasma kallikrein. Biochemistry 1980; 19: 1322.
49 Gee A P, Boyle M DP, Borsos T. Distinction between C8-mediated and C8/C9-mediated hemolysis on the basis of independent ⁸⁶Rb and hemoglobin release. J Immunol 1980; 124: 1905.
50 Ghebrihewet B, Silverberg M, Kaplan A P. Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 1981; 153: 665.
51 Gigli I, Fujita T, Nussenzweig V. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc Natl Acad Sci USA 1979; 76: 6596.
52 Gigli I, Mason J W, Colman R W, Austen K F. Interactions of plasma kallikrein with Cl inhibitor. J Immunol 1970; 104: 574.
53 Gordon J L. (Ed). Platelets in Biology and Pathology. Vol. 2 Elsevier/North Holland; New York: 1981
54 Gorski J P, Howard J B. Effect of methylamine on the structure and function of the fourth component of human complement, C4. J Biol Chem 1980; 255: 10025.
55 Gorski J P, Hugli T E, Mueller-Eberhard H J. C4a: The third anaphylatoxin of the human complement system. Proc Natl Acad Sci USA 1979; 76: 5299.
56 Griffin J H, Cochrane C G. Mechanisms of involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor (coagulation Factor XII). Proc Natl Acad Sci USA 1976; 73: 2554.
57 Griffin J H, Cochrane C G. Recent advances in the understanding of contact activation reactions. Sem Thrombos Hemostas 1979; 05: 254.
58 Gurewich V, Pannell R, Luoie S, Kelley P, Suddith P, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase), a study in vitro and in two animal species. J Clin Invest 1984; 73: 1731.
59 Hammer C H, Nicholson A, Mayer M M. On the mechanism of cytolysis by complement: evidence on insertion of C5b and C7 subunits of the C5b, 6, 7 complex into phospholipid bilayers of erythrocyte membranes. Proc Natl Acad Sci USA 1975; 72: 5076.
60 Harpel P C. Human plasma α₂-macroglobulin. An inhibitor of plasma kallikrein. J Exp Med 1970; 132: 329.
61 Heimark R L, Kurachi K, Fujikawa K, Davie E W. Surface activation of blood coagulation, fibrinolysis and kinin formation. Nature 1980; 286: 456.
62 Henne D, Hugo F, Bhakdi S. Interaction of complement S-protein with thrombinantithrombin complexes: A role for the Sprotein in haemostasis. Thromb Res 1985; 38: 401.
63 Henson P M. Role of complement and leukocytes in immunologic release of vasoactive amines from platelets. Fed Proc 1969; 28: 1721.
64 Hesketh T R, Dourmarshkin R R, Payne S N, Humphrey J H, Lachmann P J. Lesions due to the complement in lipid membranes. Nature 1971; 233: 620.
65 Hiemstra P S, Daha M R, Bouma B N. Activation of Factor B of the complement system by kallikrein and its light chain. Thromb Res 1985; 38: 491.
66 Hinsbergh van V WM, Bertina R M, Wijngaarden A, Tilburg van N H, Emeis J J, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985; 65: 444.
67 Hugli T E. Complement factors and inflammation: Effects of a-thrombin on components of C3 and C5. In: Lundblad R L, Fenton J W, Mann K G. (Eds): Chemistry and Biology of Thrombin. Ann Arbor Science; Michigan: 1977: 345.
68 Hugli T E. The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a and C5a. CRC Crit Rev Immunol 1981; 02: 321.
69 Hugli T E. Interrelationships between coagulation and complement activation. In: Fareed J, Messmore H L, Fenton J W, Brinkhous K M. (Eds): Perspectives in Hemostasis. Pergamon Press; New York: 1981: 59.
70 Humphrey J H, Dourmashkin R R. The lesions in cell membranes caused by complement. Adv Immunol 1969; 11: 75.
71 Iida K, Nussenzweig V. Complement receptor is an inhibitor of the complement cascade. J Exp Med 1981; 153: 1138.
72 Isenman D E, Kells D IC, Cooper N R, Müller-Eberhard H J, Pangburn M K. Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3blike functional properties. Biochemistry 1981; 20: 4458.
73 Isenman D E, Podack E R, Cooper N R. The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by fluid phase C3/C5 convertase. J Immunol 1980; 124: 326.
74 Jackson C M, Nemerson Y. Blood coagulation. Ann Rev Biochem 1980; 49: 765.
75 Janatova J, Tack B F, Prahl J W. Third component of human complement: Structural requirements for its function. Biochemistry 1980; 19: 4479.
76 Johnson M S, Gagnon J, Reid K BM. Factor D of the alternative pathway of human complement. Purification, alignment and N-terminal amino acid sequences of the major cyanogen bromide fragments, and localization of the serine residue at the active site. Biochem J 1980; 187: 863.
77 Kadish J L, Butterfield C E, Folkman J. The effect of fibrin on cultured vascular endothelial cells. Tissue Cell 1979; 11: 99.
78 Kaplan A P, Austen K F. The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med 1972; 136: 1378.
79 Kaplan A P, Ghebrehiwet B, Silverberg M, Sealey J E. The intrinsic coagulationkinin pathway, complement cascades, plasma renin-angiotensin system, and their interrelationsships. CRC Crit Rev Immunol 1981; 03: 75.
80 Kane W H, Lindhout M J, Jackson C M, Majerus P W. Factor Va-dependent binding of Factor Xa to human platelets. J Biol Chem 1980; 255: 1170.
81 Kazatchkine M D, Fearon D T, Metcalfe D D, Rosenberg R D, Austen K F. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest 1981; 67: 223.
82 Kazatchkine M D, Fearon D T, Silbert J E, Austen K F. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med 1979; 150: 1202.
83 Kenney D M, Davis A E. Association of alternative complement pathway components with human blood platelets: secretion and localization of Factor D and beta 1H globulin. Clin Immunol Immunopathol 1981; 21: 351.
84 Kerbiriou D M, Griffin J H. High molecular weight kininogen. Studies of structurefunction relationships and of proteolysis of the molecule occurring during contact activation of plasma. J Biol Chem 1979; 254: 12020.
85 Kernbaum S, Batin R, Wautier J-L, Bure A, Gougerot M, Peltier A P. Human deficiency of the sixth component of complement in a patient with meningococcal meningitis and no haemostasis abnormality. Biomedicine 1980; 33: 197.
86 Kolb W P, Haxby J A, Arroyave C M, Müller-Eberhard H J. Molecular analysis of the membrane attack mechanism of complement. J Exp Med 1972; 135: 549.
87 Kolb W P, Kolb L M. Antithrombin III binding to SC5b-9 attack complexes of human complement: Dissociation of a modified antithrombin III derivative subsequent to complex formation. Biochemistry 1983; 22: 496.
88 Kolb W P, Kolb L M, Savary J R. Biochemical characterization of the sixth component (C6) of human complement. Biochemistry 1982; 21: 294.
89 Kolb W P, Müller-Eberhard H J. The membrane attack mechanism of complement: isolation and subunit composition of the C5b-9 complex. J Exp Med 1975; 141: 724.
90 Kramer W, Müller-Berghaus G. Effect of platelet antiserum on the activation of intravascular coagulation by endotoxin. Thromb Res 1977; 10: 47.
91 Kraut J. Serine proteases: Structure and mechanism of catalysis. Ann Rev Biochem 1977; 46: 331.
92 Lachmann P J, Thompson R A. Reactive lysis : The complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as Cl. J Exp Med 1970; 131: 629.
93 Lachmann P J, Thompson R A. Reactive lysis. The complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C5, 6 and the participation of C8 and C9. J Exp Med 1970; 131: 643.
94 Laurell A-B, Johnson U, Martensson U, Sjoholm A G. Formation of complexes composed of Clr, Cls and Cl inactivator in human serum on activation of Cl. Acta Path Microbiol Scand 1978; 86: 299.
95 Law S K, Levine R P. Interaction between the third complement protein and cell surface macromolecules. Proc Natl Acad Sci USA 1977; 74: 2701.
96 Law S K, Lichtenberg N A, Levine R P. Covalent binding and hemolytic activity of complement proteins (inactivation by amines). Proc Natl Acad Sci USA 1980; 77: 7194.
97 Law S A, Minich T M, Levine R P. Binding reaction between the third human complement protein and small molecules. Biochemistry 1981; 20: 7457.
98 Lepow I H, Wurz L, Ratnoff O D, Pillemer L. Studies on the mechanism of inactivation of human complement by plasmin and by antigen-antibody aggregates. J Immunol 1954; 73: 146.
99 Lesavre P H, Hugli T E, Esser A F, Müller-Eberhard H J. The alternative pathway C3/C5 convertase: chemical basis of Factor B activation. J Immunol 1979; 123: 529.
100 Levin E G. Latent tissue plasminogen activator produced by human endothelial cells in culture : Evidence for an enzymeinhibitor complex. Proc Natl Acad Sci USA 1983; 80: 6804.
101 Levin E G, Loskutoff D J. Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. J Cell Biol 1982; 94: 631.
102 Lijnen H R, Collen D. Interaction of plasminogen activators and inhibitors with plasminogen and fibrin. Sem Thromb Haemostas 1982; 08: 2.
103 Lijnen H R, Hoef van B, Collen D. Interaction of heparin with histidine-rich glycoprotein and with antithrombin III. Thromb Haemostas 1983; 50: 560.
104 Lint T F, Behrends C L, Gewürz H. Serum lipoproteins and C567-INH activity. J Immunol 1977; 119: 883.
105 Lipinski B, Gurewich B. The effect of leukopenia versus thrombocytopenia on endotoxin-induced intravascular coagulation. Thromb Res 1976; 08: 403.
106 Loos M, Volanakis J E, Stroud R M. Mode of interaction of different polyanions with the first (Cl, Cl), the second (C2)binding site(s) on Cl by polyanions. Immunochemistry 1976; 13: 789.
107 Lorand L, Credo R B, Janus T J. Factor XIII (Fibrin-Stabilizing Factor). Methods Enzymol 1981; 80: 333.
108 Loskutoff D J, Edgington T S. An inhibitor of plasminogen activator in rabbit endothelial cells. J Biol Chem 1981; 256: 4142.
109 MacFarlane R G. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964; 202: 498.
110 Mandle R, Kaplan A P. Hageman factor substrates. Human plasma prekallikrein: mechanisms of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. J Biol Chem 1977; 252: 6097.
111 Mandle R J, Kaplan A P. Hageman factordependent fibrinolysis generation of fibrinolytic activity by the interaction of human activated factor XI and plasminogen. Blood 1979; 54: 850.
112 Mann J, O’Brien R, Hostetter M K, Alper C A, Rosen F S, Babior B M. The third component of complement: covalent attachment of a radioactive sugar to the labile binding site of C3 via the alternative pathway. J Immunol 1981; 126: 2370.
113 Mardiney M R, Müller-Eberhard H J, Feldman J D. Ultrastructural localization of the third and fourth components of complement on complement-cell complexes. Am J Pathol 1968; 53: 253.
114 Marlar R A, Kleiss A J, Griffin J H. An alternative extrinsic pathway of human blood coagulation. Blood 1982; 60: 1353.
115 Mayer M M. Mechanism of cytolysis by complement. Proc Natl Acad Sci USA 1972; 69: 2954.
116 McLeod B C, Baker P, Gewürz H. Studies on the inhibition of C56-initiated lysis (reactive lysis). III. Characterization of the inhibitory activity C567-INH and its mode of action. Immunology 1975; 28: 133.
117 Medicus R G, Götze O, Müller-Eberhard H J. The serine protease nature of the C3 and C5 convertase of the classical and alternative complement pathways. Scand J Immunol 1976; 05: 1049.
118 Messmore H L. Natural inhibitors of the coagulation system. Sem Thromb Hemostas 1982; 08: 267.
119 Miletich J P, Jackson C M, Majerus P W. Properties of the Factor Xa binding site on human platelets. J Biol Chem 1978; 253: 6908.
120 Minta J O, Lepow I H. Studies on the subunit structure of human properdin. Immunochemistry 1974; 11: 361.
121 Muhlfelder T W, Niemetz J, Kreutzer D, Beebe D. C5 chemotactic fragment induces leukocyte production of tissue factor activity. J Clin Invest 1979; 63: 147.
122 Müller-Berghaus G. Beziehungen zwischen Komplement und Blutgerinnung. Klin Wschr 1977; 55: 663.
123 Müller-Berghaus G. The role of platelets, leukocytes, and complement in the activation of intravascular coagulation by endotoxin. In: de Gaetano G, Garattini S. (Eds): Platelets : A Multidisciplinary Approach. Raven Press; New York: 1978: 303.
124 Müller-Berghaus G, Lasch H-G. Microcirculatory Disturbances Induced by Generalized Intravascular Coagulation. In: Born G VR, Eichler O, Farah A, Herken H, Welch A D. (Eds): Handbuch der experimentellen Pharmakologie. Springer; Heidelberg/New York: 1975: 420.
125 Müller-Berghaus G, Lohmann E. The role of complement in endotoxin-induced disseminated intravascular coagulation: Studies in congenitally C6-deficient rabbits. Br J Haematol 1974; 28: 403.
126 Müller-Eberhard H J. The membrane attack complex. Springer Sem Immunopathol 1984; 07: 93.
127 Müller-Eberhard H J, Fjellström K-E. Isolation of the anticomplementary protein from cobra venom and its mode of action on C3. J Immunol 1971; 107: 1666.
128 Müller-Eberhard H J, Götze O. C3 proactivator convertase and its mode of action. J Exp Med 1972; 135: 1003.
129 Müller-Eberhard H J, Schreiber R D. Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol 1980; 29: 1.
130 Mustard J F, Packham M A. Factors influencing platelet function : Adhesion, release and aggregation. Pharmacol Rev 1970; 22: 97.
131 Nemerow G R, Yamamoto K I, Lint T F. Restriction of complement mediated membrane in the eighth component of complement: a dual role for C8 in the complement sequence. J Immunol 1979; 123: 1245.
132 Nemerson Y, Furie B. Zymogens and cofactors of blood coagulation. CRC Crit Rev Biochem 1980; 09: 45.
133 Niemetz J. Coagulant activity of leukocytes: Tissue factor activity. J Clin Invest 1972; 51: 307.
134 Osterud B. Activation pathways of the coagulation system in normal haemostasis. Scand J Haematol 1984; 32: 337.
135 Osterud B, Rapaport S I. Activation of Factor IX by the reaction product of tissue factor and Factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260.
136 Ogston D, Bennett B. (Eds): Hemostasis: Biochemistry, Physiology and Pathology. Wiley; New York: 1977
137 Owen W G. The control of hemostasis. Arch Pathol Lab Med 1982; 106: 209.
138 Owen W G, Esmon C T. Functional properties of an endothelial cell cofactor for thrombin catalyzed activation of Protein C. J Biol Chem 1981; 256: 5532.
139 Pangburn M K, Müller-Eberhard H J. Relation of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3 to biological targets of complement. J Exp Med 1980; 152: 1102.
140 Pangburn M K, Müller-Eberhard H J. The alternative pathway of complement. Springer Semin Immunopathol 1984; 07: 163.
141 Pangburn M K, Schreiber R D, MüllerEberhard H J. Human complement C3 inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein βlH for cleavage of C3b and C4b in solution. J Exp Med 1977; 146: 257.
142 Pangburn M K, Schreiber R D, MüllerEberhard H J. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med 1981; 154: 856.
143 Pangburn M K, Schreiber R D, MüllerEberhard H J. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 1983; 80: 5430.
144 Pangburn M K, Schreiber R D, Trombold J S, Müller-Eberhard H J. Paroxysmal nocturnal hemoglobinuria: deficiency in Faktor H-like functions of the abnormal erythrocytes. J Exp Med 1983; 157: 1971.
145 Petersen B H, Graham J A, Brooks G F. Human deficiency of the eighth component of complement. The requirement of C8 for serum Neisseria gonorrhoeae bactericidal activity. J Clin Invest 1976; 57: 283.
146 Pfueller S L, Lüscher E F. Studies of the mechanisms of the human platelet release reaction induced by immunologic stimuli. II. The effect of zymosan. J Immunol 1974; 112: 1211.
147 Pillemer L, Ratnoff O D, Bluf L, Lepow I H. The inactivation of complement and its components by plasmin. J Exp Med 1953; 97: 573.
148 Pillemer L, Blum L, Lepow I FI, Ross O A, Todd E W, Wardlaw A C. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 1954; 120: 279.
149 Podack E R, Biesecker G, Müller-Eberhard H J. Membrane attack complex of complement: generation of high affinity phospholipid binding sites by fusion of five hydrophilic plasma proteins. Proc Natl Acad Sci USA 1979; 76: 897.
150 Podack E R, Esser A F, Biesecker G, Müller-Eberhard H J. Membrane attack complex of complement: a structural analysis of its assembly. J Exp Med 1980; 151: 301.
151 Podack E R, Müller-Eberhard H J. Binding of desoxycholate, phosphatidyl choline vesicles, lipoprotein and of the Sprotein to complexes of terminal complement components. J Immunol 1978; 121: 1025.
152 Podack E R, Müller-Eberhard H J. Isolation of human S-protein, an inhibitor of the membrane attack complex of complement. J Biol Chem 1979; 254: 9908.
153 Podack E R, Müller-Eberhard H J. Limited proteolysis of C5b-6: Functional stability of the degraded complex. J Immunol 1980; 124: 332.
154 Podack E R, Müller-Eberhard H J. SC5b-9 complex of complement: formation of the dimeric membrane attack complex by removal of S-protein. J Immunol 1980; 124: 1779.
155 Podack E R, Preissner K T, Müller-Eberhard H J. Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein. Acta Pathol Microbiol Immunol Scand 1984; (C) 92 (Suppl) 284: 89.
156 Podack E R, Tschopp J. Polymerization of the ninth component of complement (C9) : formation of poly C9 with a tubular ultrastructure resembling the membrane attack complex of complement. Proc Natl Acad Sci USA 1982; 79: 574.
157 Podack E R, Tschopp J. Membrane attack by complement. Mol Immunol 1984; 21: 589.
158 Podack E R, Tschopp J, Müller-Eberhard H J. Molecular organization of C9 within the membrane attack complex of complement: induction of circular C9 polymerization by the C5b-8 assembly. J Exp Med 1982; 156: 268.
159 Polley M J, Nachman R. The human complement system in thrombin-mediated platelet function. J Exp Med 1978; 147: 1713.
160 Polley M J, Nachman R L, Weksler B B. Human complement in the arachidonic acid transformation pathway in platelets. J Exp Med 1981; 153: 257.
161 Porter R R, Reid K BM. The biochemistry of complement. Nature 1978; 275: 699.
162 Preissner K T, Müller-Berghaus G. Sprotein modulates the heparin-catalyzed inhibition of thrombin by antithrombin III. Evidence for a direct interaction of Sprotein with heparin. Eur J Biochem. 1986 (in press).
163 Preissner K T, Podack E R, Müller-Eberhard H J. Localization of the S-protein within the inhibitor complexes SC5b-7, SC5b-8, and SC5b-9 of human complement. Immunobiol 1983; 164: 286A.
164 Preissner K T, Podack E R, Müller-Eberhard H J. The membrane attack complex of complement: relation of C7 to the metastable membrane binding site of the intermediate complex C5b-7. J Immunol 1985; 135: 445.
165 Preissner K T, Podack E R, Müller-Eberhard H J. Self-association of the seventh component of human complement (C7): dimerization and polymerization. J Immunol 1985; 135: 452.
166 Preissner K T, Wassmuth R, Müller-Berghaus G. Physicochemical characterization of human S-protein and its function in the coagulation system. Biochem J 1985; 231: 349.
167 Prydz H, Allison A C, Schorlemmer H U. Further link between complement activation and blood coagulation. Nature 1977; 270: 173.
168 Radcliffe R, Nemerson Y. Activation and control of factor VII by activated factor X and thrombin. J Biol Chem 1975; 250: 388.
169 Radcliffe R, Nemerson Y. Mechanisms of activation of bovine Factor VII. J Biol Chem 1976; 251: 4797.
170 Ratnoff O D, Naff G B. The conversion of Cls to Cl esterase by plasmin and trypsin. J Exp Med 1967; 125: 337.
171 Ratnoff O D, Saito H. Amidolytic properties of single-chain activated Hageman factor. Proc Natl Acad Sci USA 1979; 76: 1461.
172 Reid K BM, Porter R R. The proteolytic activation systems of complement. Ann Rev Biochem 1981; 50: 433.
173 Rosenberg R D. Chemistry of the hemostatic mechanism and its relationship to the action of heparin. Fed Proc 1977; 36: 10.
174 Rosing J, Tans G, Govers-Riemslag J WP, Zwaal R FA, Hemker H C. The role of phospholipids and Factor Va in the prothrombinase complex. J Biol Chem 1980; 255: 274.
175 Rosse W F. Erythrocyte disorders paroxysmal nocturnal hemoglobinuria. In: Williams W J, Beutler E, Erselv A J, Rundles R W. (Eds): Hematology. McGraw-Hill; New York: 1972: 460.
176 Schmaier H H, Smith P M, Colman R W. Platelet Cl inhibitor. A secreted alphagranule protein. J Clin Invest 1985; 75: 242.
177 Schreiber A D, Kaplan A P, Austen K F. Inhibition by Cl-INH of Hageman factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest 1973; 52: 1402.
178 Smith C A, Pangburn M K, Vogel C-W, Müller-Eberhard H J. Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement. J Biol Chem 1984; 259: 4582.
179 Stolfi R L. Immune lytic transformation: a state of irreversible damage generated as a result of the reaction of the eighth component in the guinea pig complement system. J Immunol 1968; 100: 46.
180 Sundsmo J S, Fair D S. Relationships among the complement, kinin, coagulation, and fibrinolytic systems. Springer Semin Immunopathol 1983; 06: 231.
181 Sundsmo J S, Wood L M. Activated Factor B (Bb) of the alternative pathway of complement cleaves and activates plasminogen. J Immunol 1981; 127: 877.
182 Tack B F, Harrison R A, Janatova J. Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci USA 1980; 77: 5764.
183 Thompson R A, Rowe D S. Reactive hemolysis: a distinct form of red cell lysis. Immunology 1968; 14: 745.
184 Tranum-Jensen J, Bhakdi S, Bhakdi-Lehnen B, Bjerrum O J, Speth V. Complement lysis: the ultrastructure and orientation of the C5b-9 complex on target sheep erythrocyte membranes. Scand J Immunol 1978; 07: 45.
185 Travis J, Salvesen G S. Human plasma proteinase inhibitors. Ann Rev Biochem 1983; 52: 655.
186 Tschopp J, Müller-Eberhard H J, Podack E R. Formation of transmembrane tubules by spontaneous polymerization of the tetramolecular C9 polymerization of hydrophilic complement protein C9. Nature 1982; 298: 534.
187 van de Waart P. The role of Factor Va in the formation and function of the prothrombinase complex. Dissertation, Maastricht. 1984
188 Vogel C-W, Müller-Eberhard H J. The cobra venom factor-dependent C3 convertase of human complement. J Biol Chem 1982; 257: 8292.
189 Vogel C-W, Plückthun A, Podack E R, Dennis E A, Müller-Eberhard H J. The membrane attack complex of complement and its precursor proteins lack phospholipase activity. Mol Immunol 1983; 20: 377.
190 Vogel C-W, Smith C A, Müller-Eberhard H J. Cobra venom factor: structural homology with the third component of human complement. J Immunol 1984; 133: 3235.
191 Von Zabern I, Nolte R, Vogt W. Treatment of human complement components C4 and C3 with amines or chaotropic ions. Scand J Immunol 1981; 13: 413.
192 Walker F J. Regulation of activated Protein C by a new protein. A possible function for bovine Protein S. J Biol Chem 1980; 255: 5521.
193 Ward P A. A plasmin-split fragment of C3 as a new chemotactic factor. J Exp Med 1967; 126: 189.
194 Wautier J L, Souchon H, Reid K BM, Peltier A P, Caen J P. Studies on the mode of reaction of the first component of complement with platelets: Interaction between collagen-like portion of Clq and platelets. Immunochemistry 1977; 14: 763.
195 Weigle W, Goodman M G, Morgan E L, Hugli T E. Regulation of immune response by components of the complement cascade and their activated fragments. Springer Semin Immunpathol 1983; 06: 173.
196 Weiler J M, Daha M R, Austen K F, Fearon D T. Control of the amplification convertase of complement by the plasma protein ßlH. Proc Natl Acad Sci USA 1976; 73: 3268.
197 Weiler J M, Yurt R M, Fearon D T, Austen K F. Modulation of the formation of the amplification convertase of complement by native and commercial heparin. J Exp Med 1978; 147: 409.
198 Wiggins R C, Bouma B N, Cochrane C G, Griffin J H. Role of high molecular weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. Proc Natl Acad Sci USA 1977; 74: 4636.
199 Wiggins R C, Giclas P C, Henson P M. Chemotactic activity generated from the fifth component of complement by plasma kallikrein of rabbit. J Exp Med 1981; 153: 1391.
200 Wilson C B, Brenner B M, Stein J H. (Eds). Immunologic Mechanisms of Renal Disease. Contemporary Issues in Nephrology». Vol 3 Churchill Livingstone; New York: 1979
201 Wiman B, Collen D. Molecular mechanism of physiological fibrinolysis. Nature 1978; 272: 549.
202 Wooldrigde D, Spragg J, Austen K F. Interaction of Hageman Factor-dependent systems with the complement sequence. In: Pisano J J, Austen K F. (Eds): Chemistry and Biology of the Kallikrein-Kinin Systems in Health and Disease. National Inst of Health Monograph; Bethesda, Maryland: 1974: 221.
203 Ziccardi R J. The first component of human complement (Cl): Activation and control. Springer Semin Immunopathol 1983; 06: 213.
204 Zucker M B, Grant R A. Aggregation and release reaction induced in human blood platelets by zymosan. J Immunol 1974; 112: 1219.
205 Zucker M B, Grant R A, Alper C A, Goodkofsky I, Lepow I H. Requirement for complement components and fibrinogen in the zymosan-induced release reaction of human blood platelets. J Immunol 1974; 113: 1744.
206 Zwaal R FA. Membrane and lipid involvement in blood coagulation. Biochim. Biophys. Acta 1978; 515: 163.